NO994027D0 - Polymorf av zopolrestat-monohydrat - Google Patents

Polymorf av zopolrestat-monohydrat

Info

Publication number
NO994027D0
NO994027D0 NO994027A NO994027A NO994027D0 NO 994027 D0 NO994027 D0 NO 994027D0 NO 994027 A NO994027 A NO 994027A NO 994027 A NO994027 A NO 994027A NO 994027 D0 NO994027 D0 NO 994027D0
Authority
NO
Norway
Prior art keywords
polymorph
zopolrestat monohydrate
zopolrestat
monohydrate
Prior art date
Application number
NO994027A
Other languages
English (en)
Other versions
NO994027L (no
Inventor
John Francis Lambert
Timothy Norris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO994027D0 publication Critical patent/NO994027D0/no
Publication of NO994027L publication Critical patent/NO994027L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
NO994027A 1998-08-21 1999-08-20 Polymorf av zopolrestat-monohydrat NO994027L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (2)

Publication Number Publication Date
NO994027D0 true NO994027D0 (no) 1999-08-20
NO994027L NO994027L (no) 2000-02-22

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994027A NO994027L (no) 1998-08-21 1999-08-20 Polymorf av zopolrestat-monohydrat

Country Status (31)

Country Link
US (1) US6159976A (no)
EP (1) EP0982306A3 (no)
JP (1) JP2000072769A (no)
KR (1) KR20000017411A (no)
CN (1) CN1245804A (no)
AP (1) AP9901662A0 (no)
AU (1) AU4453299A (no)
BG (1) BG103674A (no)
BR (1) BR9903873A (no)
CA (1) CA2280590A1 (no)
EA (1) EA199900675A3 (no)
EE (1) EE9900385A (no)
GT (1) GT199900137A (no)
HR (1) HRP990259A2 (no)
HU (1) HUP9902783A3 (no)
ID (1) ID23307A (no)
IL (1) IL131419A0 (no)
IS (1) IS5155A (no)
MA (1) MA26678A1 (no)
NO (1) NO994027L (no)
NZ (1) NZ337363A (no)
OA (1) OA11150A (no)
PA (1) PA8480601A1 (no)
PE (1) PE20000993A1 (no)
PL (1) PL335016A1 (no)
SG (1) SG83147A1 (no)
TN (1) TNSN99159A1 (no)
TR (1) TR199901996A2 (no)
UY (1) UY25668A1 (no)
YU (1) YU39899A (no)
ZA (1) ZA995297B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105732640B (zh) 2010-07-16 2019-01-08 纽约市哥伦比亚大学理事会 醛糖还原酶抑制剂及其用途
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
WO2014126885A1 (en) * 2013-02-13 2014-08-21 Mylari Banavara L Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
MX2018016122A (es) 2016-06-21 2019-08-01 Univ Columbia Inhibidores de aldosa reductasa y metodos de uso.
CN111065392A (zh) 2017-07-28 2020-04-24 应用治疗公司 用于治疗半乳糖血症的组合物和方法
CA3132136A1 (en) 2019-04-01 2020-10-08 Andrew Wasmuth Inhibitors of aldose reductase
EP4125909A1 (en) 2020-03-31 2023-02-08 Applied Therapeutics Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
CA3176768A1 (en) 2020-05-01 2021-11-04 Shoshana SHENDELMAN Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (en) * 1990-08-28 1992-03-05 Pfizer Inc. 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
IL120264A0 (en) * 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
PL335016A1 (en) 2000-02-28
OA11150A (en) 2003-04-16
TNSN99159A1 (fr) 2005-11-10
NZ337363A (en) 2001-01-26
EP0982306A2 (en) 2000-03-01
EP0982306A3 (en) 2000-07-05
YU39899A (sh) 2002-12-10
NO994027L (no) 2000-02-22
EE9900385A (et) 2000-04-17
AP9901662A0 (en) 1999-09-30
BR9903873A (pt) 2000-09-19
CA2280590A1 (en) 2000-02-21
IL131419A0 (en) 2001-01-28
ZA995297B (en) 2001-02-19
GT199900137A (es) 2001-02-09
EA199900675A2 (ru) 2000-02-28
EA199900675A3 (ru) 2000-06-26
US6159976A (en) 2000-12-12
PA8480601A1 (es) 2000-09-29
TR199901996A2 (xx) 2000-03-21
ID23307A (id) 2000-04-05
IS5155A (is) 2000-02-22
PE20000993A1 (es) 2000-10-04
HUP9902783A3 (en) 2001-01-29
JP2000072769A (ja) 2000-03-07
UY25668A1 (es) 2001-08-27
HRP990259A2 (en) 2000-06-30
CN1245804A (zh) 2000-03-01
AU4453299A (en) 2000-03-09
SG83147A1 (en) 2001-09-18
HUP9902783A2 (hu) 2000-12-28
HU9902783D0 (en) 1999-10-28
MA26678A1 (fr) 2004-12-20
KR20000017411A (ko) 2000-03-25
BG103674A (en) 2000-03-31

Similar Documents

Publication Publication Date Title
EE200000642A (et) Suurendatud saagisega FAPalfa-spetsiifilised antikehad
ID27092A (id) Pembuatan ftalat anhidrida
NO20006395D0 (no) Polymorf form av clopidogrel-hydrogensulfat
NO20011083L (no) Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
PT1119430E (pt) Fresa
NO20010899D0 (no) Forbedring av ugunstige apomorfin-effekter
NO20011886D0 (no) Utforminger av fexofenadin
ID28208A (id) Konstruksi penegang pengapung
NO20010298L (no) Polymorf av et formakum
NO994790L (no) Estimering av permabilitet
FI19992855A (fi) Valaisuolosuhteiden mittaus
NO20023072L (no) Syntese av krystallinske silikoaluminofosfater
ID25901A (id) Proses pembuatan 4-aminometil-pirolidin-3-on terlindung
PT1246817E (pt) Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetra-hidropiridilo
NO994027D0 (no) Polymorf av zopolrestat-monohydrat
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
NO20010553D0 (no) Krystallinske former av osanetant
NO20006262D0 (no) Fôring av rör
NO20002012D0 (no) Nye polymorfe former av cipamfylline
ID24327A (id) Produksi senyawa-senyawa avermektin
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
NO20012276D0 (no) Identifisering av SENV-genotyper
NO20020183D0 (no) Fremgangsmåte for deacylering av lipodepsipeptider
PT1175417E (pt) Compostos substituidos de benzolactamas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application